CTOs on the Move

TopoTarget USA

www.apoxis.com

 
TopoTarget USA is a Rockaway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.apoxis.com
  • 100 Enterprise Dr
    Rockaway, NJ USA 07866
  • Phone: 973.895.6900

Executives

Name Title Contact Details

Similar Companies

Harvard MedTech

Harvard Medtech`s mission is to solve pain and related afflictions by providing unmatched Tele-PainCare™ solutions that promote safe, effective healing holistically and organically in conjunction with, or preferably in lieu of, surgery and prescription pain medications. Our Vx Pain Relief Program uniquely integrates state-of-the-art Virtual Reality Therapy with Behavioral Health Clinicians, who regularly provide psychological and social interventions by telephone to patients in the comfort of their homes while keeping the prescribing physician apprised of the patient`s progress. Our FDA-registered, clinically validated, whole-person approach to delivering safe, effective, at-home care yields more complete, convenient, timely and affordable relief of pain, depression, anxiety and related afflictions while requiring zero investment by the prescribing physician.

Saniona

Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical

Mega Aid Compounding Pharmacy

Mega Aid is a full service specialty and compounding pharmacy, serving physicians and their patients.

Brightstone Transitions

Brightstone specializes in creating a customized support program for young people needing help through mentoring. Brightstone uses an action oriented approach that creates learning opportunities through real life situations. Our participants move beyon...

Kyowa Hakko Kirin

Kyowa Kirin North America is a fully integrated specialty pharmaceutical company, where people work together to understand clinical needs and opportunities for innovation that can result in real advances for patients. Since 2018, the North American organization has received approval from the US Food and Drug Administration (FDA) to market 3 first-in-class medicines – achievements we share with the scientific, medical, and advocacy communities who contributed greatly to the success of these programs.